NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8 | -78.4% | 13,675 | -16.6% | 0.00% | -80.0% |
| Q4 2022 | $37 | -100.0% | 16,394 | -29.5% | 0.01% | -89.8% |
| Q4 2019 | $502,000 | +19.8% | 23,260 | +97.5% | 0.05% | +96.0% |
| Q2 2019 | $419,000 | +46.0% | 11,780 | -48.6% | 0.02% | -3.8% |
| Q2 2015 | $287,000 | +50.3% | 22,907 | +44.6% | 0.03% | +30.0% |
| Q3 2014 | $191,000 | – | 15,840 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |